Qiagen (NYSE:QGEN) to Post Q4 2025 Earnings of $0.62 Per Share, William Blair Forecasts

Qiagen (NYSE:QGEN - Free Report) - Stock analysts at William Blair upped their Q4 2025 earnings per share estimates for Qiagen in a report released on Wednesday, May 1st. William Blair analyst A. Brackmann now forecasts that the company will post earnings of $0.62 per share for the quarter, up from their prior estimate of $0.61. The consensus estimate for Qiagen's current full-year earnings is $2.09 per share.

Several other research analysts have also recently issued reports on QGEN. Stifel Nicolaus decreased their price objective on shares of Qiagen from $55.00 to $45.00 and set a "hold" rating for the company in a report on Wednesday. JPMorgan Chase & Co. lifted their target price on shares of Qiagen from $50.00 to $52.00 and gave the company an "overweight" rating in a research note on Thursday, February 8th. Morgan Stanley raised Qiagen from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $49.48 to $51.00 in a research note on Friday, February 16th. Finally, Citigroup decreased their price objective on shares of Qiagen from $61.86 to $60.00 and set a "buy" rating on the stock in a research note on Thursday, February 8th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Qiagen presently has a consensus rating of "Moderate Buy" and an average target price of $50.95.

Qiagen Stock Up 0.7 %

NYSE QGEN traded up $0.30 during trading hours on Friday, hitting $42.98. The company had a trading volume of 1,307,816 shares, compared to its average volume of 1,229,076. The company has a market capitalization of $9.81 billion, a price-to-earnings ratio of 28.82, a P/E/G ratio of 3.62 and a beta of 0.42. The firm's 50 day moving average is $42.53 and its 200 day moving average is $42.73. Qiagen has a fifty-two week low of $34.74 and a fifty-two week high of $47.70. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.99 and a quick ratio of 1.62.

Qiagen (NYSE:QGEN - Get Free Report) last issued its earnings results on Monday, April 29th. The company reported $0.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.44 by $0.02. Qiagen had a net margin of 17.38% and a return on equity of 12.50%. The company had revenue of $459.00 million during the quarter, compared to analysts' expectations of $453.91 million. During the same period last year, the company posted $0.53 earnings per share. The firm's quarterly revenue was down 5.4% compared to the same quarter last year.

Hedge Funds Weigh In On Qiagen

A number of large investors have recently bought and sold shares of QGEN. Norges Bank bought a new position in Qiagen in the fourth quarter worth approximately $264,322,000. Wellington Management Group LLP boosted its holdings in shares of Qiagen by 81.0% in the 3rd quarter. Wellington Management Group LLP now owns 6,054,116 shares of the company's stock valued at $245,299,000 after buying an additional 2,709,030 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Qiagen by 8.1% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 24,066,569 shares of the company's stock worth $1,045,211,000 after buying an additional 1,809,486 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in Qiagen by 33,220.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,345,488 shares of the company's stock valued at $58,435,000 after acquiring an additional 1,341,450 shares during the last quarter. Finally, Nuance Investments LLC acquired a new stake in Qiagen in the fourth quarter valued at approximately $47,479,000. Hedge funds and other institutional investors own 70.00% of the company's stock.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.